Combination of Interleukin-27 and MicroRNA for Enhancing Expression of Anti-Inflammatory and Proosteogenic Genes

Figure 2

IL-27 effect on osteoblast and osteoclast cell signaling. (a) IL-27 upregulates expression of several genes related to osteoblast differentiation pathways. Expression changes were determined by utilizing a luciferase reporter assay for indicating activity of BMP, WNT, STAT1, STAT3, OPN, RUNX2, and OSX promoters. Black rectangle frames (□) highlight the data with significant expression changes relative to untreated or negative control (pOB−ctrl); +OB ctrl, differentiating MC3T3E1-14 osteoblasts treated with differentiation supplements for 72 h. Right plot, IL-27 upregulates osteoblast differentiation genes and downregulates osteoblast inhibitor genes, as assessed by quantitative real time (qPCR) assays. ( relative to untreated or negative control, pOB−ctrl). (b) IL-27 downregulates proinflammatory genes in fibroblasts and differentiation genes in osteoclasts, as assessed by quantitative real time (qPCR) assays ( versus untreated controls). Right plot, IL-27 treatment downregulates several pathways associated with osteoclast activity as assessed by luciferase reporter assay for indicating activity of TNF, IL-17a, TRAF2, STAT3, and STAT1 promoters. Black rectangle frames (□) highlight the data with significant expression changes () relative to untreated or negative control (pOB−ctrl); +OB ctrl, differentiating MC3T3E1-14 osteoblasts treated with differentiation supplements for the days indicated.

(a)

(b)